High-Affinity Monoclonal Antibody Against AGR2 in Pancreatic Cancer
Author Information
Author(s): Robinson Reeder M., Reyes Leticia, Christopher Benjamin N., Duncan Ravyn M., Burge Rachel A., Siegel Julie, Nasarre Patrick, Wang Pingping, O’Bryan John P., Hobbs G. Aaron, Klauber-DeMore Nancy, Dolloff Nathan G., Benhar Itai
Primary Institution: Medical University of South Carolina
Hypothesis
The study investigates the expression and function of AGR2 in pancreatic ductal adenocarcinoma (PDAC) and develops high-affinity monoclonal antibodies against it.
Conclusion
The study provides novel, high-affinity, fully human anti-AGR2 monoclonal antibodies that neutralize the pro-tumor effects of extracellular AGR2 in PDAC.
Supporting Evidence
- AGR2 was expressed in approximately 90% of PDAC samples but not in normal pancreas biopsies.
- The level of AGR2 expression correlated with increasing disease stage.
- High AGR2 expression was associated with significantly lower disease-free survival in pancreatic cancer patients.
- Monoclonal antibodies developed showed low picomolar binding affinity to AGR2.
Takeaway
Researchers found a protein called AGR2 that is linked to pancreatic cancer and created special antibodies to block its harmful effects.
Methodology
The study involved characterizing AGR2 expression in PDAC samples, developing monoclonal antibodies through phage display, and testing their effects on cell adhesion and migration.
Limitations
The study does not address the potential effects of AGR2 in normal tissues or its role in non-cancerous conditions.
Participant Demographics
Patients with pancreatic ductal adenocarcinoma (PDAC) were included in the study.
Statistical Information
P-Value
0.0025
Statistical Significance
p = 0.0025
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website